Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4673-4677

  Dempke, Wolfram C M ^a   Heinemann, Volker ^b  

^a Elbland Clinic Riesa   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cetuximab; Colon cancer; Drug resistance; EGFR inhibitors; K ras mutations; Review; Therapeutic outcome

Indexed keywords

B RAF KINASE; CETUXIMAB; K RAS PROTEIN; PANITUMUMAB;

COLORECTAL CARCINOMA; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; ONCOGENE RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; PROGNOSIS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 78650234994     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Dempke W and Heinemann V: Resistance to EGF-R (erbB1) and VEGF-R modulating agents. Eur J Cancer 45: 1117-1128, 2009.
2. Youssoufian H, Hicklin DJ and Rowinsky EK: Review: Monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 18(Suppl): 5544s-5548s, 2007.
3. Ciadiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174, 2008.
4. Kerbel RS: Tumor angiogenesis. N Engl J Med 358: 2039-2049, 2008.
5. Harari PM, Allen GW and Bonner JA: Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25: 4057-4065, 2007.
6. Kumar A, Petri ET, Halmos B and Boggon TJ: Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26: 1742-1751, 2008.
7. Grant S, Fisher PB and Dent P: The role of signal transduction pathways in drug and radiation resistance. Cancer Treat Res 112: 89-108, 2002.
8. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE and Ellis LM: Molecular mechanisms of resistance to therapies targeting the epidermal growth factor. Clin Cancer Res 11: 397-405, 2005.
9. Malumbres M and Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465, 2003.
10. Downward J: Role of receptor tyrosine kinases in G-protein-coupled receptor regulation of Ras: transactivation or parallel pathways? Biochem J 376(Pt 3): e9-10, 2003.
11. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R and Mariadason JM: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961, 2008.
12. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C and Rougier R: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26(Suppl): abstract 2, 2008.
13. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud, FG, Volovat C, Nippgen J, Stroh C, Celik I and Koralewski P: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 26(Suppl): abstract 4000, 2008.
14. Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers G, Schrama JG, Erdkamp FL, Vos A, Mol L and Antonini NF: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26(Suppl): abstract 4011, 2008.
15. Hecht JR, Mitchell EP, Baranda J and Rodenburg CJ: Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): Final efficacy and KRAS analyses. Gastrointestinal Cancers Symposium, abstract 343, 2008.
16. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P and Frebourg T: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 166-169, 2007.
17. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, Poplin EA, Hidalgo M, Baselga J, Clark EA and Mauro DJ: Expression of epiregulin and amphiregulin and K-ras mutation status predicts disease control in metastatic colorectal cancer patients. J Clin Oncol 25: 3230-3237, 2007.
18. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD and Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
19. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F and Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
20. De Rook W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E and Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515, 2008.
21. Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A and Jänne PA: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 99: 83-89, 2008. (Pubitemid 351920237)
22. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ and Rowinsky EK: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24: 4914-4921, 2006.
23. Tejpar S, Peeters M, Humblet Y, Vermorken JB, De Hertogh G, De Roock W, Nippgen J, von Heydebreck A, Stroh C and Van Cutsem E: Relationship of efficacy with KRAS status (wild-type versus mutant) in patients with irinotecan- refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). J Clin Oncol 26(Suppl): abstract 400, 2008.
24. Maity A, Pore N, Lee J, Solomon D and O'Rourke DM: Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphoinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60: 5879-5886, 2000.
25. Ravindranath N, Wion D, Brachet P and Djakiew D: Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22: 432-443, 2001.
26. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ and Koeppen H: Association of K-ras, B-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97: 981-989, 2005.
27. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
28. Dempke W: Farnesyltransferase inhibitors - a novel approach in the treatment of advanced pancreatic carcinomas. Anticancer Res 23(Suppl 2A): 813-818, 2003.